AbbVie Inc.
ABBVHealthcareNASDAQDrug Manufacturers - General · Last scanned Jun 3, 2026
Scan Results
Daily timeframePart of the healthcare sector, AbbVie Inc. (ABBV) is listed under Drug Manufacturers - General. At a $380.57B market cap, AbbVie Inc. ranks as a mega-cap company within healthcare. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
Market Cap
$380.57B
Beta
0.30
P/E (TTM)
105.07
P/E (Fwd)
13.27
EPS (TTM)
$2.05
EPS (Fwd)
$16.23
ROE
—
ROA
10.0%
Cash
$9.39B
Total Debt
$72.91B
Free CF
$20.81B
52W Change
15.0%
Annual Financials
Cash vs Debt
On the balance sheet, ABBV has $9.39B in cash with $72.91B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $20.81B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on assets of 10.0% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $56.20B (2021) to $61.16B (2025).
The relatively low beta of 0.30 suggests ABBV is a less volatile holding compared to the broader index. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence AbbVie Inc.'s trajectory.